Log In Get Started
Press Releases April 6, 2026 08:00 PM

LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference

LeMaitre Vascular to Present at Needham Virtual Healthcare Conference

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
LMAT

LeMaitre Vascular, Inc., a developer and manufacturer of vascular devices for peripheral vascular disease treatment, announced its upcoming management presentation at the 25th Annual Needham Virtual Healthcare Conference scheduled for April 16, 2025.

LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
LMAT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • LeMaitre specializes in devices and implants for peripheral vascular disease affecting over 200 million worldwide.
  • The company targets vascular surgeons with its disposable and implantable vascular devices.
  • The management team will present at a significant healthcare investment conference, indicating efforts to engage with investors and the healthcare sector.

BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.

About LeMaitre

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.


Risks

  • Peripheral vascular disease treatment market is competitive, posing challenges for market share growth.
  • Dependence on vascular surgeons as core customers may limit diversification opportunities.
  • The impact of future healthcare regulations and reimbursement policies may affect sales and profitability.

More from Press Releases

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026 Traws Pharma Provides Regulatory Update on Influenza Program Jun 12, 2026 Heartland Express, Inc. Declares Regular Quarterly Dividend Jun 12, 2026